| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Case Control Study |
| Article Title |
Characteristic dysbiosis in patients with type 2 diabetes and hyperuricemia, and the effect of empagliflozin on gut microbiota
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin-Ru Deng, Yu-Jia Zhai, Xiao-Yang Shi, Sha-Sha Tang, Yuan-Yuan Fang, Hong-Yan Heng, Ling-Yun Zhao and Hui-Juan Yuan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82270865 |
| Henan Provincial Key Research and Development Projects |
No. 231111313200 |
| Henan Provincial Medical Science and Technology Research Program-the Provincial and Ministerial Major Projects |
No. SBGJ202301002 |
| Scientific and Technological Project in Henan Province |
No. LHGJ20190614 |
|
| Corresponding Author |
Hui-Juan Yuan, MD, Professor, Department of Endocrinology, Henan Provincial Key Medicine Laboratory of Intestinal Microecology and Diabetes, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou 450003, Henan Province, China. hjyuan@zzu.edu.cn |
| Key Words |
Type 2 diabetes; Hyperuricemia; Uric acid; Empagliflozin; Gut microbiota |
| Core Tip |
Patients with type 2 diabetes (T2DM) have a significantly higher prevalence of hyperuricemia (HUA) than non-diabetic patients and are more likely to suffer from cardiovascular diseases. In recent years, the gut microbiota has been shown to play a crucial role in metabolic diseases, including T2DM and HUA. Thus, the gut microbiota may be a new therapeutic target for HUA. Empagliflozin significantly lowers serum uric acid levels and contributes to cardiovascular benefits which are partly attributed to altered gut microbiota. This study revealed that empagliflozin administered to patients with characteristic dysbiosis due to T2DM and HUA, may have gut microbiota involved in purine metabolism partially restored. |
| Publish Date |
2025-02-28 10:47 |
| Citation |
<p>Deng XR, Zhai YJ, Shi XY, Tang SS, Fang YY, Heng HY, Zhao LY, Yuan HJ. Characteristic dysbiosis in patients with type 2 diabetes and hyperuricemia, and the effect of empagliflozin on gut microbiota. <i>World J Diabetes</i> 2025; 16(4): 102970</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i4/102970.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i4.102970 |
